Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients

Am J Hematol. 2020 Apr;95(4):E86-E89. doi: 10.1002/ajh.25721. Epub 2020 Jan 23.

Authors

Giacomo Coltro^{1

2

3}, Guadalupe Antelo¹, Terra L Lasho¹, Christy M Finke¹, Animesh Pardanani¹, Naseema Gangat¹, Ryan M Carr¹, Moritz Binder¹, Abhishek A Mangaonkar¹, Rhett Ketterling⁴, Martin E Fernandez-Zapico⁵, Keith D Robertson⁵, Alberto Bosi², Alessandro M Vannucchi^{2

3}, Ayalew Tefferi¹, Mrinal M Patnaik¹

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, Minnesota.
² Haematology Unit, Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy.
³ CRIMM, Centro di Ricerca e Innovazione per le Malattie Mieloproliferative, AOU Careggi, Firenze, Italy.
⁴ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.
⁵ Schulze Center for Novel Therapeutics, Division of Oncology Research, Mayo Clinic, Rochester, Minnesota.

PMID: 31925810
DOI: 10.1002/ajh.25721

No abstract available

Publication types

Letter

MeSH terms

Adult
Age Factors
Aged
Aged, 80 and over
Codon, Nonsense*
DNA-Binding Proteins / genetics*
Dioxygenases
Disease Progression
Follow-Up Studies
Frameshift Mutation*
Genetic Association Studies*
Humans
Infant
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / epidemiology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Male
Middle Aged
Myelodysplastic Syndromes / blood
Myelodysplastic Syndromes / genetics*
Myelodysplastic Syndromes / mortality
Myeloproliferative Disorders / blood
Myeloproliferative Disorders / genetics*
Myeloproliferative Disorders / mortality
Neoplasm Proteins / genetics*
Prognosis
Proto-Oncogene Proteins / genetics*
Survival Analysis
Treatment Outcome

Substances

Codon, Nonsense
DNA-Binding Proteins
Neoplasm Proteins
Proto-Oncogene Proteins
Dioxygenases
TET2 protein, human